MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
MangoRx, a developer of men's health products, announced that its Australian patent application for a new preventive care technology has been accepted. This follows a similar acceptance in Japan. The technology targets respiratory and orally transmitted infections using a formulation with GALALCOOL®️, zinc protoporphyrin IX, and tannins. This patent strengthens their global intellectual property portfolio, especially following MangoRx's recent acquisition of Intramont Technologies' patents. The official patent publication is set for June 6, 2024, with an anticipated deed issuance by September 6, 2024, barring any opposition. This move aligns with MangoRx’s mission to offer advanced health solutions worldwide.
- Notice of Acceptance for Australian Patent Application strengthens MangoRx's global IP portfolio.
- Recent patent acceptance in Japan enhances the company's market reach.
- The technology targets a wide range of infections, offering comprehensive preventive care.
- Acquisition of Intramont Technologies' patents boosts MangoRx's innovation capabilities.
- Potential for commercializing products in the Australian market.
- Formulation includes GALALCOOL®️, zinc protoporphyrin IX, and tannins, known for inhibiting various pathogens.
- The patent deed is subject to a Notice of Opposition within three months, posing a potential risk.
- Commercial success in Australia is uncertain and depends on market acceptance.
Insights
The acceptance of MangoRx's patent application in Australia represents a significant step in the company's strategy to expand its global footprint. From a market research perspective, this patent could open new revenue streams in the Australian market, which is known for its high demand for innovative health products. The use of GALALCOOL®️, zinc protoporphyrin IX and select tannins positions MangoRx's product as a unique offering in the preventive care space.
This technological advancement strengthens MangoRx's position in the competitive landscape of oral health and preventive care. Investors should note that the Australian healthcare market is regulated and successful commercialization will depend on navigating these regulations effectively. Moreover, the acceptance could enhance brand credibility, making it easier to penetrate other international markets.
Implications for stakeholders: In the short term, there may not be immediate revenue impact until the product enters the market. In the long term, however, the patent could provide a competitive edge and contribute to sustained growth. Investors should watch for the issuance of the official patent deed and subsequent product launches.
Financially, the acceptance of this patent could be significant for MangoRx. Patents can provide a competitive advantage by preventing competitors from using similar technology, which can lead to increased market share and pricing power. The Australian market, while smaller than the U.S., still offers substantial opportunities for revenue growth.
However, investors should consider the costs associated with bringing a new product to market, including regulatory approval, marketing and distribution. These expenses can be substantial and may impact short-term profitability. The potential financial benefits are long-term, assuming successful market penetration and consumer adoption.
Financial risks: If the patent faces opposition or if there are delays in product approval, it could affect the financial outlook. Therefore, it's important to monitor the company's progress in these areas closely.
The inclusion of GALALCOOL®️, zinc protoporphyrin IX and select tannins in MangoRx's patented formulation is noteworthy from a healthcare standpoint. These components are known for their antimicrobial properties. GALALCOOL®️, in particular, has been studied for its effectiveness in combating oral pathogens, which could make this product a valuable tool in preventive healthcare.
Healthcare benefits: Preventive care products like these can reduce the incidence of common respiratory infections, which can lead to decreased healthcare costs and improved public health outcomes. The use of such formulations in easily accessible forms like toothpaste or lozenges can promote better compliance among users.
However, clinical validation in the Australian context will be essential to establish efficacy and safety. Investors should be aware of the potential need for further clinical trials or studies before widespread adoption.
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/022903.
Following the Company’s recent receipt of a Notice of Allowance from Japan, this additional patent acceptance from Australia forges a significant milestone following MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies on April 24, 2024. The Notice of Acceptance covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus (HPV). Acceptance of the application will officially be published in the Australian Official Journal of Patents on June 6, 2024.
Jacob Cohen, Co-Founder and CEO of MangoRx commented, “Receiving this Notice of Acceptance in Australia is yet another critical step in our strategy to protect and commercialize our innovative preventive care technology on a global basis. It further underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience. This patent not only fortifies our intellectual property but also paves the way for introducing our cutting-edge products to the Australian market.”
The patented technology is designed to prevent illnesses acquired through the oral cavity and pharynx using an orally available solution, such as toothpaste, oral dissolvable tablets (ODT), lozenges, or mouthwash. The unique formulation features GALALCOOL®️, zinc protoporphyrin IX, and select tannins, which work synergistically to inhibit various pathogens, offering comprehensive protection against respiratory infections.
This expansion aligns with MangoRx’s mission to enhance well-being through innovative health solutions. The official patent deed is anticipated to be issued on or around September 6, 2024 and is subject to issuance upon receipt of a Notice of Opposition within three months from the acceptance advertisement. Receiving a patent issuance in Australia would join an already robust portfolio of U.S. and international patents, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement; the Company’s stockholders’ equity as of the Company’s next fiscal quarter end; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock at
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
SOURCE: Mangoceuticals Inc.
FAQ
What recent patent acceptance did MangoRx receive?
What does the new patent cover for MangoRx?
How does the new patent acceptance in Australia impact MangoRx?
What are the key ingredients in MangoRx's patented formulation?
When will the Australian patent be officially published?
What is the anticipated date for the patent deed issuance in Australia?
